Significance of experimental infarct size as an indicator of therapeutic efficacy in humans.
Nikolaos
N
Sakellaridis
Demetrius
D
Panagopoulos
D000818:Animals; D002544:Cerebral Infarction / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D006801:Humans; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors; D011379:Prognosis; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D014409:Tumor Necrosis Factor-alpha; D052247:Nitric Oxide Synthase Type II